News> News & Event

Mindray to Acquire a Controlling Stake in Shanghai Long Island

We are pleased to announce that Mindray has recently reached an equity transfer agreement with Shanghai Long Island Biotec. Co., Ltd. (“Long Island”) to acquire a controlling stake in the company.

The deal will strengthen Mindray’s research and development, manufacturing and sales capabilities in thrombotic and hemostatic reagent products – new growth areas for the company. The acquisition will also enable Mindray to provide customers with better and more comprehensive solutions, and meet growing market needs for stringent surgery screening tests and cardiovascular disease detection.

Mindray will leverage its R&D, manufacturing, quality assurance, and sales and marketing platforms to support Long Island’s future development and achieve full integration.

Mindray will keep on strengthening Long Island’s thrombotic and hemostatic reagent business, and will maintain Long lsland’s current sale and after-sale service policies. We have no plan to change Long Island’s employee base and will honor all of Long Island’s contracts as agreed upon prior to the acquisition.

We believe that the collaboration between Mindray and Long Island will bring many synergies to both parties. We expect the combined company to provide better products and services to our customers, broaden development opportunities for our employees, and help Long Island establish a stronger position to compete in the marketplace.

About Long Island:

Located in Zhuanghang Park, Fengxian Disctrict, Shanghai, China, Long lsland Biotec. Co., Ltd. focuses on developing and manufacturing high-quality  innovative thrombotic and hemostatic reagents, and maintains its leading position in thrombotic and hemostatic testing business. Please refer to for more information.

Shenzhen Mindray Biomedical Electronics Co., Ltd.

Jan. 9. 2014

Mindray to Acquire a Controlling Stake in Shanghai Long Island

Open WeChat and Scan the QR code .Get the Webpage and Share on Moments.